For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 33,470 | 28,261* | 25,469 | 24,309 |
| General and administrative expenses | 8,528 | 7,907* | 7,475 | 7,143 |
| Total operating expenses | 41,998 | 36,168 | 32,944 | 31,452 |
| Loss from operations | -41,998 | -36,168* | -32,944 | -31,452 |
| Interest and other income, net | 2,693 | 3,170 | 3,076 | 3,354 |
| Total other income | 2,693 | 3,170* | 3,076 | 3,354 |
| Net loss | -39,305 | -32,998* | -29,868 | -28,098 |
| Unrealized loss on marketable securities, net | -286 | -8* | 6 | -252 |
| Comprehensive loss | -39,591 | -33,006 | -29,862 | -28,350 |
| Basic EPS | -0.64 | -0.554 | -0.5 | -0.47 |
| Diluted EPS | -0.64 | -0.554 | -0.5 | -0.47 |
| Basic Average Shares | 61,746,050 | 59,585,456 | 59,670,757 | 59,550,771 |
| Diluted Average Shares | 61,746,050 | 59,585,456 | 59,670,757 | 59,550,771 |
Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (TYRA)